William Cox, DO
Family Medicine · Selah, WANPI 1184717936
Payments from drug & device makers
Across 262 payments — averaging $31.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Bayer$621
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$489
- Otsuka America Pharmaceutical, Inc.$424
- GSK$396
- Pfizer$348
- plus $3K from 26 others
What the payments were for
- Food & beverage$8,00197%
- Education$2073%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 67 | $3,222 |
| Bayer | 23 | $621 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $489 |
| Otsuka America Pharmaceutical, Inc. | 12 | $424 |
| GSK | 15 | $396 |
| Pfizer | 24 | $348 |
| Amgen | 15 | $335 |
| AbbVie(2 entities) | 15 | $312 |
| Novo Nordisk | 11 | $261 |
| Johnson & Johnson(2 entities) | 4 | $244 |
| Boehringer Ingelheim | 6 | $208 |
| Novartis | 7 | $194 |
| Astellas Pharma US Inc | 2 | $170 |
| Sanofi-aventis U.S. LLC | 6 | $108 |
| Lundbeck LLC | 5 | $105 |
| Teva Pharmaceuticals USA, Inc. | 1 | $92 |
| Dexcom, Inc. | 2 | $91 |
| Merck | 2 | $91 |
| E.r. Squibb & Sons, L.L.C. | 4 | $71 |
| Sunovion Pharmaceuticals Inc. | 2 | $70 |
| Kowa Pharmaceuticals America, Inc. | 4 | $56 |
| Lilly USA, LLC | 3 | $51 |
| Abbott | 2 | $49 |
| Exact Sciences | 2 | $41 |
| Sanofi Pasteur Inc. | 2 | $32 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Zyla Life Sciences, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Radius Health, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$810
- AIRSUPRA$471
- CAPLYTA$211
- BREZTRI$125
- ABILIFY ASIMTUFII$122
- ABILIFY MAINTENA$122
- REXULTI$119
- INVOKANA$113
How this compares
$8,208 in reported general payments places this provider in the 95th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 76 | $62,493 |
| EliquisApixaban | 39 | $36,785 |
| OzempicSemaglutide | 33 | $32,702 |
| JardianceEmpagliflozin | 23 | $27,446 |
| VraylarCariprazine Hcl | 15 | $21,180 |
| XareltoRivaroxaban | 14 | $16,534 |
| MyrbetriqMirabegron | 22 | $13,825 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $11,823 |
| TrulicityDulaglutide | 12 | $11,728 |
| NeuproRotigotine | 13 | $11,150 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $9,331 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,289 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 15 | $7,300 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $4,537 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $4,374 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $3,222 | $74,652104 claims |
| PfizerEliquis, Prempro | $348 | $39,63652 claims |
| Novo NordiskOzempic | $261 | $32,70233 claims |
| Boehringer IngelheimJardiance | $208 | $27,44623 claims |
| AbbVieVraylar | $312 | $21,18015 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $396 | $21,15432 claims |
| Johnson & JohnsonXarelto | $244 | $16,53414 claims |
| Astellas Pharma US IncMyrbetriq | $170 | $13,82522 claims |
| Lilly USA, LLCTrulicity | $51 | $11,72812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Selah
- Anton GraschWenatchee$5.3M
- Gaylon KippBellevue$4.8M
- Steven KasterWenatchee$4M
- Angela EakinSpokane$3M
- Jonathan StabenCheney$2.5M
- Emily ZaragozaSeattle$1.9M
- Brad FrandsenPort Orchard$1.7M
- Kevin HatfieldSeattle$527K
- Steven SmithAuburn$438K
- John RobinsonEdmonds$425K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.